Tygh Capital Management Inc. Acquires 25,332 Shares of Repligen Co. (RGEN)

Tygh Capital Management Inc. grew its holdings in Repligen Co. (NASDAQ:RGEN) by 24.2% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 130,041 shares of the biotechnology company’s stock after purchasing an additional 25,332 shares during the period. Tygh Capital Management Inc.’s holdings in Repligen were worth $7,212,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Lisanti Capital Growth LLC raised its holdings in shares of Repligen by 55.7% in the third quarter. Lisanti Capital Growth LLC now owns 44,405 shares of the biotechnology company’s stock valued at $2,463,000 after purchasing an additional 15,880 shares during the last quarter. American Capital Management Inc. acquired a new stake in shares of Repligen in the third quarter valued at approximately $3,866,000. Victory Capital Management Inc. raised its holdings in shares of Repligen by 56.7% in the third quarter. Victory Capital Management Inc. now owns 10,451 shares of the biotechnology company’s stock valued at $580,000 after purchasing an additional 3,781 shares during the last quarter. Ardevora Asset Management LLP acquired a new stake in shares of Repligen in the third quarter valued at approximately $5,937,000. Finally, Arizona State Retirement System raised its holdings in shares of Repligen by 3.3% in the third quarter. Arizona State Retirement System now owns 56,556 shares of the biotechnology company’s stock valued at $3,137,000 after purchasing an additional 1,818 shares during the last quarter. Institutional investors own 93.38% of the company’s stock.

Shares of RGEN opened at $65.82 on Wednesday. The firm has a market cap of $2.86 billion, a P/E ratio of 95.39, a PEG ratio of 5.12 and a beta of 0.74. Repligen Co. has a 1-year low of $29.56 and a 1-year high of $70.50.

Repligen (NASDAQ:RGEN) last issued its earnings results on Thursday, November 1st. The biotechnology company reported $0.20 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.18 by $0.02. The business had revenue of $49.53 million for the quarter, compared to the consensus estimate of $46.69 million. Repligen had a net margin of 12.61% and a return on equity of 5.39%. The firm’s revenue for the quarter was up 35.4% on a year-over-year basis. During the same period in the previous year, the company earned $0.15 earnings per share. Analysts anticipate that Repligen Co. will post 0.73 EPS for the current year.

In other Repligen news, Director Nicolas Barthelemy sold 6,580 shares of Repligen stock in a transaction on Wednesday, August 29th. The shares were sold at an average price of $54.44, for a total transaction of $358,215.20. Following the completion of the transaction, the director now directly owns 8,774 shares of the company’s stock, valued at $477,656.56. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Thomas F. Ryan, Jr. sold 2,366 shares of Repligen stock in a transaction on Wednesday, August 22nd. The stock was sold at an average price of $51.44, for a total transaction of $121,707.04. Following the transaction, the director now directly owns 4,988 shares of the company’s stock, valued at $256,582.72. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 52,735 shares of company stock worth $2,950,017. 1.40% of the stock is owned by corporate insiders.

A number of research firms have recently issued reports on RGEN. William Blair reiterated an “outperform” rating on shares of Repligen in a report on Friday, November 2nd. HC Wainwright reiterated a “hold” rating and issued a $60.00 price objective on shares of Repligen in a report on Monday, November 5th. BidaskClub upgraded shares of Repligen from a “buy” rating to a “strong-buy” rating in a report on Friday, August 24th. Zacks Investment Research downgraded shares of Repligen from a “hold” rating to a “sell” rating in a report on Tuesday, August 7th. Finally, Citigroup lifted their price objective on shares of Repligen from $45.00 to $56.00 and gave the company a “buy” rating in a report on Friday, July 20th. Four investment analysts have rated the stock with a hold rating, four have given a buy rating and two have issued a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $63.00.

WARNING: “Tygh Capital Management Inc. Acquires 25,332 Shares of Repligen Co. (RGEN)” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece on another site, it was stolen and republished in violation of United States & international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.dispatchtribunal.com/2018/11/14/tygh-capital-management-inc-acquires-25332-shares-of-repligen-co-rgen.html.

About Repligen

Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process worldwide. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media.

See Also: How Short Selling Works

Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Co. (NASDAQ:RGEN).

Institutional Ownership by Quarter for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply